FDA: Shining A New Light On Benefit-Risk Analysis
In furtherance of the Transparency Initiative launched in 2009, the U.S. Food and Drug Administration (FDA) published its first-ever guidance document on benefit-risk analysis for medical devices. This groundbreaking document is...To view the full article, register now.
Already a subscriber? Click here to view full article